Elenestinib
Advanced Systemic Mastocytosis
Blueprint Medicines CorporationSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Advanced Systemic Mastocytosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Imatinib Novartis Pharmaceuticals | Phase 2 | B |
Avapritinib Blueprint Medicines Corporation | Phase 2 | B |
Brentuximab Vedotin Jason Robert Gotlib | Phase 2 | B |
Denileukin Diftitox M.D. Anderson Cancer Center | Phase 2 | CCC |
Bezuclastinib Cogent Biosciences, Inc. | Phase 2 | CCC |
View all 15 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →